Bifogade filer
Kurs
+9,02%
Kalender
Est. tid* | ||
2025-02-25 | - | Bokslutskommuniké 2024 |
2024-11-29 | - | Kvartalsrapport 2024-Q3 |
2024-08-29 | - | Kvartalsrapport 2024-Q2 |
2024-06-28 | - | Årsstämma |
2024-05-31 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2024-05-14 | - | Kvartalsrapport 2024-Q1 |
2024-02-27 | - | Bokslutskommuniké 2023 |
2023-10-27 | - | Extra Bolagsstämma 2023 |
2023-10-27 | - | Kvartalsrapport 2023-Q3 |
2023-08-30 | - | Kvartalsrapport 2023-Q2 |
2023-05-31 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2023-05-30 | - | Årsstämma |
2023-05-12 | - | Kvartalsrapport 2023-Q1 |
2023-02-17 | - | Bokslutskommuniké 2022 |
2022-10-27 | - | Kvartalsrapport 2022-Q3 |
2022-08-24 | - | Kvartalsrapport 2022-Q2 |
2022-05-17 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2022-05-16 | - | Årsstämma |
2022-05-12 | - | Kvartalsrapport 2022-Q1 |
2022-02-22 | - | Bokslutskommuniké 2021 |
2021-11-12 | - | Kvartalsrapport 2021-Q3 |
2021-08-27 | - | Kvartalsrapport 2021-Q2 |
2021-06-04 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2021-06-03 | - | Årsstämma |
2021-05-12 | - | Kvartalsrapport 2021-Q1 |
2021-02-12 | - | Bokslutskommuniké 2020 |
2020-11-13 | - | Kvartalsrapport 2020-Q3 |
2020-08-28 | - | Kvartalsrapport 2020-Q2 |
2020-06-05 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2020-06-04 | - | Årsstämma |
2020-05-15 | - | Kvartalsrapport 2020-Q1 |
2020-02-14 | - | Bokslutskommuniké 2019 |
2019-11-15 | - | Kvartalsrapport 2019-Q3 |
2019-08-28 | - | Kvartalsrapport 2019-Q2 |
2019-05-27 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2019-05-24 | - | Årsstämma |
2019-05-17 | - | Kvartalsrapport 2019-Q1 |
2019-02-14 | - | Bokslutskommuniké 2018 |
2018-11-21 | - | Kvartalsrapport 2018-Q3 |
2018-06-05 | - | Årsstämma |
2018-05-24 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2018-05-16 | - | Kvartalsrapport 2018-Q1 |
2018-02-16 | - | Bokslutskommuniké 2017 |
2017-12-11 | - | Extra Bolagsstämma 2017 |
2017-10-25 | - | Kvartalsrapport 2017-Q3 |
2017-08-30 | - | Kvartalsrapport 2017-Q2 |
2017-05-24 | - | X-dag ordinarie utdelning CYXO 0.00 SEK |
2017-05-23 | - | Årsstämma |
2017-05-16 | - | Kvartalsrapport 2017-Q1 |
2017-02-16 | - | Bokslutskommuniké 2016 |
2016-10-28 | - | Kvartalsrapport 2016-Q3 |
2016-08-24 | - | Kvartalsrapport 2016-Q2 |
Beskrivning
Land | Sverige |
---|---|
Sektor | Hälsovård |
Industri | Bioteknik |
Cyxone (publ), a biotech company in autoimmune diseases, have received approvals from the Medical Product Agency (Office for Registration of Medicinal Products, Medical devices and Biocides) and the Central Ethics Committee in Poland to start a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA).
"The approval is a very important milestone for us. Cyxone have now finally the possibility to initiate the greatest and foremost value-building activity ever in the company's history. Receiving this green light from Poland, which will be the most important country for the upcoming study, is really great and a big achievement. We are now looking forward to continuing working towards our goal to be able to offer a safe and user-friendly treatment which also contributes to improved quality of life for the patient," says Carl-Magnus Högerkorp, acting CEO, Cyxone.
The study is a multicenter, randomised, double-blinded, placebo-controlled clinical study where patients with moderate to severe RA, who have previously been treated with methotrexate with inadequate response, will be treated with Rabeximod for 24 weeks. The aim of the study is to confirm the therapeutic efficacy of Rabeximod in this patient population, as well as to expand the safety data documentation.
Rabeximod is a well-tolerated, orally available Phase 2 candidate drug with a unique mechanism of action. Rabeximod selectively targets the inflammatory macrophage, a type of white blood cell which is the central orchestrator of the inflammatory process that causes tissue destruction and clinical symptoms in RA. Combined with the convenience of oral administration and a beneficial tolerability profile, this opens up for treatment in the early as well as later stages of the disease. It is believed to be particularly effective at onset and relapses of RA, with good potential to prevent joint destruction and progression of the disease.
Contact
Carl-Magnus Högerkorp, acting CEO
Tel: +46 (0)70 781 88 12
Email: carl.hogerkorp@cyxone.com
About Cyxone
Cyxone AB (publ) (Nasdaq First North Growth Market: CYXO) develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis. Rabeximod is a Phase 2 candidate drug being evaluated for the management of rheumatoid arthritis. T20K is a Phase 1 candidate drug for treatment of multiple sclerosis. Certified Adviser is FNCA Sweden AB. For more information, please visit www.cyxone.com